Dutch Startup Raises €1.675 Million to Bring Hospital-Grade Heart Testing to Family Doctors
Netherlands, Wednesday, 18 February 2026.
HeartEye’s breakthrough allows family doctors to perform professional 12-channel ECG recordings in under one minute, potentially revolutionizing cardiac care access and reducing unnecessary hospital referrals.
Healthtech Innovation Streamlines Cardiac Diagnostics
This represents a significant advancement in healthtech, specifically targeting cardiovascular diagnostics through portable medical technology [1]. HeartEye’s innovation addresses a critical gap in healthcare delivery by making hospital-grade cardiac monitoring accessible in primary care settings and potentially in patients’ homes [1]. The technology transforms what has traditionally been a time-consuming and complex process requiring trained hospital professionals into a simple procedure that can be completed by general practitioners, assistants, or nurses in under one minute [1].
How the Mobile ECG Technology Works
HeartEye’s patented mobile 12-channel ECG recorder operates as a fully wireless, handheld device that delivers professional-grade heart diagnostics outside traditional hospital environments [1]. The system enables healthcare providers to create comprehensive heart recordings quickly and easily, with the data transmitted through a digital platform where it can be shared with physicians or specialists for interpretation and diagnosis support [1]. This streamlined approach allows for early detection of heart conditions while preventing unnecessary hospital referrals, contributing to more efficient care delivery, reduced costs, and decreased healthcare system pressure [1].
Strategic Investment Led by ROM InWest
The €1.675 million funding round was spearheaded by ROM InWest, with notable participation from prominent technology entrepreneurs including Schuberg Philis co-founder Pim Berger and Mphasis co-founder Jeroen Tas [1][2]. Health Innovations, marking its second investment in HeartEye, also joined the funding round [1][3]. ROM InWest Investment Manager Sara Schaafsma explained that the firm sees its role as guiding HeartEye through the critical certification phase, noting that venture capital partners typically enter either during prototype development or after CE certification when technological and market risks are significantly reduced [3].
Regulatory Path and Market Preparation
The funding will support HeartEye through the capital-intensive Medical Device Regulation (MDR) certification process, a mandatory requirement before clinical use and commercial sales can commence [1]. During this period, the company will conduct pivotal clinical studies and advance its AI-software development while building production capacity to meet anticipated demand following market approval [1]. Schaafsma emphasized that HeartEye’s innovative ECG recorder will make a direct and sustainable contribution to healthcare system resilience and affordability, positioning the company for substantial growth as a leading player that stimulates high-quality employment and knowledge development in the region, partly through collaboration with Amsterdam UMC [3].